Skip to main content
Tesamorelin Compound

An inference-console reading of the tesamorelin literature — what the GHRH(1-44) analogue's trials actually established, what stays investigational, and how it compares with sermorelin — with every confidence level surfaced honestly.

WHERE THE TESAMORELIN FACTS CAME FROM

Tesamorelin studies and source list

Match each bracketed number to the study below. PMID and DOI are lookup codes that help you find the exact paper.

Return to the main findingsRead the short answers

How to find a tesamorelin study

Researchers first changed tesamorelin so a brain hormone lasted longer in blood, and the sources below show what happened once people received the drug during planned care. They include Phase 3, a late study meant to check benefit and harm, plus the liver-fat study, blood-timing work, and a 2026 review of five trials.

Each source gives the journal and year. Some also show a PMID or DOI. These are lookup codes used by libraries and study websites. For any claim you want to check, find its bracketed number in the list below.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH); 2018. ↗
  6. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-294. ↗
  7. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. ↗
  8. Norman C, Miles J, Bowers CY, Veldhuis JD. Differential pulsatile secretagogue control of GH secretion in healthy men. Am J Physiol Regul Integr Comp Physiol. 2013;304:R712-9. ↗
  9. Veldhuis JD, Keenan DM, et al. Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. Eur J Endocrinol. 2009;161:293-300. ↗
  10. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. ↗
  11. Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS. 2011;25(10):1281-1288. ↗
  12. Lake JE, La K, Erlandson KM, Adrian S, Yenokyan G, Scherzinger A, Dube MP, Stanley T, Grinspoon S, Falutz J, Mamputu JC, Marsolais C, McComsey GA, Brown TT. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS. 2021;35(9):1395-1402. ↗
  13. Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B. Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS One. 2015;10(10):e0140358. ↗
  14. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. ↗
  15. Uçaktürk E, Nemutlu E. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry. J Pharm Biomed Anal. 2026. ↗